Health Care·Life Sciences Tools & Services·$8.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.63 | N/A | +4.82% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.63 | N/A | +4.82% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to client value. However, no specific guidance was provided for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our clients.
The earnings report indicates that Charles River Laboratories performed better than expected in terms of earnings per share, which contributed to a positive stock reaction, with shares rising 4.08%. The lack of revenue data and future guidance may leave some investors cautious, but the EPS beat suggests underlying strength in the company's operations.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STRYKER CORP
Oct 31, 2022